153 related articles for article (PubMed ID: 7606820)
21. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
22. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
23. p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
Gonzalez K; Fong C; Buzin C; Sommer SS; Saldivar JS
Curr Protoc Hum Genet; 2008 Apr; Chapter 10():Unit 10.10. PubMed ID: 18428420
[TBL] [Abstract][Full Text] [Related]
24. The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder.
Yao Z; Sherif ZA
Oncotarget; 2016 Sep; 7(39):62976-62988. PubMed ID: 27542210
[TBL] [Abstract][Full Text] [Related]
25. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
[TBL] [Abstract][Full Text] [Related]
26. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
27. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
28. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
[TBL] [Abstract][Full Text] [Related]
29. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
30. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
31. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
32. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
Leblanc T; Soussi T
Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
[TBL] [Abstract][Full Text] [Related]
33. The Evolution of Tumors in Mice and Humans with Germline p53 Mutations.
Levine AJ; Chan CS; Dudgeon C; Puzio-Kuter A; Hainaut P
Cold Spring Harb Symp Quant Biol; 2015; 80():139-45. PubMed ID: 26642854
[TBL] [Abstract][Full Text] [Related]
34. TP53 tumor-suppressor gene and human carcinogenesis.
Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
Exp Dermatol; 1993 Jun; 2(3):99-105. PubMed ID: 8162331
[TBL] [Abstract][Full Text] [Related]
35. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p53 tumor suppressor gene in families with multiple glioma patients.
Paunu N; Syrjäkoski K; Sankila R; Simola KO; Helén P; Niemelä M; Matikainen M; Isola J; Haapasalo H
J Neurooncol; 2001 Dec; 55(3):159-65. PubMed ID: 11859970
[TBL] [Abstract][Full Text] [Related]
37. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: a review.
Soussi T; Leblanc T; Baruchel A; Schaison G
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):33-6. PubMed ID: 8511038
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.
MacGeoch C; Turner G; Bobrow LG; Barnes DM; Bishop DT; Spurr NK
J Med Genet; 1995 Mar; 32(3):186-90. PubMed ID: 7783166
[TBL] [Abstract][Full Text] [Related]
39. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
40. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.
Phang BH; Othman R; Bougeard G; Chia RH; Frebourg T; Tang CL; Cheah PY; Sabapathy K
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6349-58. PubMed ID: 26578795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
